Cerebrovascular outpatient clinic (Dpt. of Neurology)
- Address
- Zaluzanskeho 15, Ostrava, Czechia
Cerebrovascular Outpatient Clinic - Neurology Department
This specialized cerebrovascular outpatient clinic within the Department of Neurology focuses on the complex management of patients with cerebrovascular disorders, particularly those requiring careful anticoagulation decisions. The center demonstrates expertise in treating high-risk patient populations where the balance between preventing ischemic events and avoiding bleeding complications is critical.
- Atrial fibrillation management in patients with prior intracranial hemorrhage
- Stroke prevention strategies in complex anticoagulation scenarios
- Novel oral anticoagulant therapy optimization in high-risk cerebrovascular patients
The clinic is actively involved in advancing clinical evidence for managing patients with atrial fibrillation who have survived intracranial hemorrhage, addressing one of neurology's most challenging treatment dilemmas. Their research evaluates the safety and efficacy of anticoagulation strategies, including edoxaban therapy, versus alternative medical management approaches to reduce the risk of recurrent stroke and systemic embolism while minimizing bleeding risk in this vulnerable population.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Cerebrovascular outpatient clinic (Dpt. of Neurology)
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Edoxaban Versus Nonanticoagulant Therapy in High-Risk Atrial Fibrillation Patients with Prior Intracranial Hemorrhage | Hamilton Health Sciences Corporation, PHRI Population Health Research Institute International | Phase III | Not Recruiting | Dec 2024 | Jul 2026 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Edoxaban | 1 | Unknown | 2024-12-09 | 2024-12-09 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.